Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen

Large-cap biotech stocks to check out in the stock market today.

2 Large Cap Biotech Stocks To Watch Right Now

Gilead (GILD) obtains positive opinion for the use of Veklury in COVID-19 patients with severe renal impairment, including those on dialysis, from the European Medicines Agency's CHMP.

Gilead's (GILD) Veklury Gets Positive CHMP View for Extended Use

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion for the use of Veklury® (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis. The European Commission (EC) will review the CHMP recommendation and, if adopted, Veklury will become the first and only authorized antiviral COVID-19 treatment t.

CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis

ACADIA Pharma

Agios Pharmaceuticals

ARK Genomic Revolution Multi-Sector ETF

VanEck Vectors Biotech ETF

BioMarin Pharmaceutical

CareDx

Exact Sciences

Exelixis

First Trust NYSE Arca Biotechnology Index Fund

FibroGen

iShares Nasdaq Biotechnology ETF

Ionis Pharma

IQVIA Hlds

Madrigal Pharmaceuticals

Moderna

Pacific Biosciences of California

Regeneron Pharmaceuticals

Seagen

Teladoc

TG Therapeutics

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

Here are the five best biotech ETFs to invest in right now.

Investing in Biotech ETFs

AbbVie

Johnson & Johnson

AbbVie's current headwinds are only temporary. Gilead Sciences' business remains rock-solid.

3 Relatively Safe Stocks to Buy if a Recession Is on the Way

Albemarle

Royal Caribbean Cruises

Even the most experienced investors have only so many hours in the day to perform their due diligence. That's where analyst ratings can be helpful.

3 Analyst Upgrades That Smart Investors Won't Ignore

Bristol-Myers

Cigna

Centene

Labcorp Holdings Inc

Organon & Co

Pfizer

Viatris

The stocks our screen found are cheap, relative to highfliers like Eli Lilly, and many are cheap for a reason.

9 Cheap Healthcare Stocks to Consider

FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 30 abstracts during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. These data reinforce the strength of Gilead and Kite Oncology's transformative science in hard-to-treat cancers. “The breadth of data being presented at ASCO is a testament to our commitment in helping to bring more life to people with cancer,” said Bill Grossman, MD, P.

Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Cindy Perettie will join the company as Executive Vice President of Kite, a Gilead Company, overseeing the cell therapy business, and will become a member of Gilead's senior leadership team, effective May 30. Ms. Perettie brings with her extensive experience in oncology and a commitment to improving patient care. Most recently, she was Head of Roche's Molecular Lab Solutions where she oversaw the PCR.

Gilead Appoints Cindy Perettie Executive Vice President of Kite

Gilead Sciences, Inc. (NASDAQ:GILD ) RBC Capital Markets Global Healthcare Conference May 16, 2023 11:00 AM ET Company Participants Merdad Parsey - Chief Medical Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Brian Abrahams Good morning. I'm Brian Abrahams, one of the senior biotech analysts here at RBC Capital Markets, and welcome again.

Gilead Sciences, Inc. (GILD) Presents at RBC Capital Markets Global Healthcare Conference (Transcript)

Gilead Sciences (NASDAQ: GILD ) stock is a hot topic on Tuesday as a new price prediction builds enthusiasm among investors. BMO Capital Markets analyst Evan David Seigerman is behind today's news as he increases the firm's price target for GILD stock from $90 per share to $100 per share.

GILD Stock Price Predictions: Is Gilead Sciences Really Worth $100?

Arcus Biosciences

FOSTER CITY, Calif., & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced that the companies have expanded the previously announced research collaboration focused on oncology to include therapies for the treatment of inflammatory diseases. The expanded collaboration builds upon Gilead's growing presence in inflammatory disease and serves as a step towards broadening Arcus' capabilities and portfolio beyond oncology and i.

Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation

Gilead Sciences, Inc. (NASDAQ:GILD ) BofA Securities 2023 Health Care Conference May 9, 2023 2:20 PM ET Company Participants Andy Dickinson - CFO Conference Call Participants Geoff Meacham - Bank of America Geoff Meacham Welcome to the morning session of the BofA Healthcare Conference. So my name is Geoff Meacham.

Gilead Sciences, Inc. (GILD) Presents at BofA Securities 2023 Health Care Conference (Transcript)

Declining sales of certain drugs, including coronavirus treatment Veklury, has weighed on Gilead's earnings. Still, Gilead is the world's leader in HIV treatments -- and new products across treatment areas could boost growth down the road.

Gilead Sciences Stock: Bear vs. Bull

A jury cleared Gilead Sciences of U.S. government allegations that it violated patents held by the Centers for Disease and Prevention on an HIV prevention drug.

Gilead Sciences didn't violate government patents on HIV prevention treatment, jury finds

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San Diego. The acquisition complements Gilead's existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation. Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for infl.

Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera

Both of these drugmakers have rich pipelines that will allow them to recover from recent sales slumps. They also offer above-average dividend yields and have raised their payouts regularly over the last five years.

2 Magnificent Dividend Stocks to Buy Before the Next Recession

Gilead Sciences stock hasn't been a good investment in recent years, often underperforming the S&P 500. Declining revenue and a lack of a growth catalyst has made investors bearish on the stock.

Gilead Sciences Stock Has Only Done This in 1 of the Past 7 Years

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Hepcludex® (bulevirtide) for the treatment of adults with chronic HDV and compensated liver disease, and recommended granting full Marketing Authorisation (MA) that is no longer subject to specific obligations. Bulevirtide was initially granted conditional marketing auth.

CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV)

LOS ANGELES--(BUSINESS WIRE)--AHF Rebukes Gilead Sciences As Prime Lawbreaking Drug Profiteer.

AHF Rebukes Gilead Sciences As Prime Lawbreaking Drug Profiteer

The U.S. claims Gilead's drugs Truvada and Descovy infringe on CDC patents.

Gilead Sciences battles U.S. government in court over HIV prevention patent

Gilead Sciences saw strong sales growth in the first quarter. While sales were strong, margins took quite a substantial beating.

Gilead Sciences: A Mixed First Quarter

Gilead's (GILD) Q1 earnings and sales miss estimates due to lower Veklury sales.

Gilead's (GILD) Q1 Earnings Miss, Veklury Sales Plunge

Gilead Sciences, Inc. (GILD) Q1 2023 Earnings Call Transcript.

Gilead Sciences, Inc. (GILD) Q1 2023 Earnings Call Transcript

Gilead Sciences (GILD) came out with quarterly earnings of $1.37 per share, missing the Zacks Consensus Estimate of $1.63 per share. This compares to earnings of $2.12 per share a year ago.

News for Gilead Sciences Stock (GILD)